PMID- 28239300
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1475-2867 (Print)
IS  - 1475-2867 (Electronic)
IS  - 1475-2867 (Linking)
VI  - 17
DP  - 2017
TI  - MiR-7 inhibits progression of hepatocarcinoma by targeting KLF-4 and promises a 
      novel diagnostic biomarker.
PG  - 31
LID - 10.1186/s12935-017-0386-x [doi]
LID - 31
AB  - BACKGROUND: MicroRNAs are 22-24 nt non-coding RNAs that bind to the 3' UTR of 
      target mRNAs, thereby inducing mRNA degradation or inhibiting mRNA translation. 
      Due to their implication in the regulation of post-transcriptional processes, the 
      role of miRNAs in hepatocellular carcinoma (HCC) has been extensively studied. 
      However, the function of miR-7 in HCC remains to be demonstrated. METHODS: 50 
      paired HCC tissues and matched peritumor tissues from patients were collected. 
      The mRNA level of miR-7 was detected by qRT-PCR. The protein level of 
      Kruppel-like factor 4 (KLF-4) was determined by western blot. Cell proliferation 
      and invasive ability were measured using MTT and transwell invasion assay, 
      respectively. RESULTS: We demonstrated that miR-7 was downregulated in 50 HCC 
      tissues and the low expression of miR-7 was significantly correlate with tumour 
      size. Moreover, overexpression of miR-7 significantly inhibited the proliferation 
      and invasion of HCC cells. Over 100 target genes of miR-7 were predicted by 
      Targetscan, and KLF-4 was indicated as the most promising candidate. Luciferase 
      report assay showed that KLF-4 could be silenced by miR-7, so as to restore the 
      impairment of cell proliferation and invasion in HCC cells. CONCLUSIONS: In 
      summary, we revealed a role of miR-7-KLF-4 axis in HCC cells, and the combination 
      of both biomarkers might improve HCC diagnosis.
FAU - Wu, Weizhong
AU  - Wu W
AD  - Department of General Surgery, The Second Hospital of Hebei Medical University, 
      Shijiazhuang, 050000 Hebei China. ISNI: 0000 0004 1804 3009. GRID: grid.452702.6
FAU - Liu, Sanguang
AU  - Liu S
AD  - Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, 050000 Hebei China. ISNI: 0000 0004 1804 3009. GRID: 
      grid.452702.6
FAU - Liang, Yunfei
AU  - Liang Y
AD  - Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, 050000 Hebei China. ISNI: 0000 0004 1804 3009. GRID: 
      grid.452702.6
FAU - Zhou, Zegao
AU  - Zhou Z
AD  - Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, 050000 Hebei China. ISNI: 0000 0004 1804 3009. GRID: 
      grid.452702.6
FAU - Liu, Xueqing
AU  - Liu X
AD  - Department of Hepatobiliary Surgery, The Second Hospital of Hebei Medical 
      University, Shijiazhuang, 050000 Hebei China. ISNI: 0000 0004 1804 3009. GRID: 
      grid.452702.6
LA  - eng
PT  - Journal Article
DEP - 20170221
PL  - England
TA  - Cancer Cell Int
JT  - Cancer cell international
JID - 101139795
PMC - PMC5320717
OTO - NOTNLM
OT  - Biomarker
OT  - Diagnosis
OT  - Hepatocellular carcinoma (HCC)
OT  - Invasion
OT  - Proliferation
OT  - miR-7
EDAT- 2017/02/28 06:00
MHDA- 2017/02/28 06:01
PMCR- 2017/02/21
CRDT- 2017/02/28 06:00
PHST- 2016/09/07 00:00 [received]
PHST- 2017/01/23 00:00 [accepted]
PHST- 2017/02/28 06:00 [entrez]
PHST- 2017/02/28 06:00 [pubmed]
PHST- 2017/02/28 06:01 [medline]
PHST- 2017/02/21 00:00 [pmc-release]
AID - 386 [pii]
AID - 10.1186/s12935-017-0386-x [doi]
PST - epublish
SO  - Cancer Cell Int. 2017 Feb 21;17:31. doi: 10.1186/s12935-017-0386-x. eCollection 
      2017.